Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | FPR3 | P25089 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | CACNA2D1 | P54289 | 6/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.34 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.34 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11441028 | 0.90 | TSHR (0.47) | LMNATSHRALDH1A1FPR3FPR2 | |
| SCHEMBL8196999 | 0.81 | TSHR (0.52) | TSHRMEN1KMT2AACACBZDHHC20 | |
| SCHEMBL27193048 | 0.80 | ZDHHC20 (0.50) | TSHRALDH1A1MEN1KMT2AACACB | |
| SCHEMBL1081677 | 0.80 | TSHR (0.50) | TSHRALDH1A1ACACBZDHHC20ZDHHC2 | |
| SCHEMBL12507020 | 0.80 | LMNA (0.52) | LMNAALDH1A1FPR3FPR2CACNA2D1 | |
| SCHEMBL14065568 | 0.80 | LMNA (0.52) | LMNAALDH1A1FPR3FPR2CACNA2D1 | |
| SCHEMBL8765444 | 0.78 | ZDHHC20 (0.53) | TSHRALDH1A1MEN1KMT2AZDHHC20 | |
| SCHEMBL13224427 | 0.78 | ZDHHC20 (0.53) | TSHRALDH1A1MEN1KMT2AZDHHC20 | |
| SCHEMBL36597 | 0.78 | ZDHHC20 (0.53) | TSHRALDH1A1MEN1KMT2AZDHHC20 | |
| SCHEMBL8966072 | 0.78 | ZDHHC20 (0.53) | TSHRALDH1A1MEN1KMT2AZDHHC20 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7431944-B2 | Delivery of multiple doses of medications | CELGENE CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| EP-1607093-A1 | Improved delivery of multiple doses of medications | CELGENE CORPORATION (US) | 2005-12-21 | — | — | EP | disclosed |
| EP-1001772-B1 | IMPROVED DELIVERY OF MULTIPLE DOSES OF MEDICATIONS | CELGENE CORP (US) | 2005-10-12 | — | — | EP | disclosed |
| EP-1541147-A1 | Improved delivery of multiple doses of a methylphenidate drug | MEHTA, Atul M. (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040091532-A1 | Delivery of multiple doses of medications | MEHTA ATUL M (US) | 2004-05-13 | — | — | US | disclosed |
| US-6635284-B2 | Attention deficit disorder, methylphenidate hydrochloride in sustained release form using particles for immediate relase and others coated with an ammino methacrylate polymer; once-daily dosage form | CELEGENE CORPORATION | 2003-10-21 | — | — | US | disclosed |
| US-20030113373-A1 | DELIVERY OF MULTIPLE DOSES OF MEDICATIONS | CELGENE CORPORATION | 2003-06-19 | — | — | US | disclosed |
| EP-1001772-A4 | IMPROVED DELIVERY OF MULTIPLE DOSES OF MEDICATIONS | MEHTA ATUL M (US) | 2002-10-30 | — | — | EP | disclosed |
| EP-1001772-A1 | IMPROVED DELIVERY OF MULTIPLE DOSES OF MEDICATIONS | MEHTA, Atul M. (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999003471-A1 | IMPROVED DELIVERY OF MULTIPLE DOSES OF MEDICATIONS | MEHTA, ATUL, M. (US) | 1999-01-28 | — | — | WO | disclosed |
| US-5837284-A | Oral dosage form of dl-threo methylphenidate hydrochloride; daily dosage; includes ammonio methacrylate polymer | CELGENE CORPORATION | 1998-11-17 | — | — | US | disclosed |
| US-5422121-A | Oral dosage unit form | ROHM GMBH (DE) | 1995-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040091532-A1 | Delivery of multiple doses of medications | SLC6A3, SLC6A2, SLC6A4 | LMNA 3680/4885TSHR 1761/4885ALDH1A1 1125/4885 |
| US-20030113373-A1 | DELIVERY OF MULTIPLE DOSES OF MEDICATIONS | SLC6A3, SLC6A2, SLC6A4 | LMNA 3680/4885TSHR 1761/4885ALDH1A1 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.